These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 30120418)

  • 1. Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics.
    Dulawa SC; Janowsky DS
    Mol Psychiatry; 2019 May; 24(5):694-709. PubMed ID: 30120418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?
    Jeon WJ; Dean B; Scarr E; Gibbons A
    Curr Neuropharmacol; 2015; 13(6):739-49. PubMed ID: 26630954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients.
    Janowsky DS
    Curr Psychiatry Rep; 2011 Dec; 13(6):443-5. PubMed ID: 21976067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.
    Drevets WC; Zarate CA; Furey ML
    Biol Psychiatry; 2013 Jun; 73(12):1156-63. PubMed ID: 23200525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interest of scopolamine as a treatment of major depressive disorder].
    Rigal A; Mouchabac S; Peretti CS
    Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition.
    Johnson CR; Kangas BD; Jutkiewicz EM; Winger G; Bergman J; Coop A; Woods JH
    J Pharmacol Exp Ther; 2021 Jun; 377(3):336-345. PubMed ID: 33712507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antidepressant effects of anticholinergic drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Jun; 47(6):17-20. PubMed ID: 19585799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions.
    Drevets WC; Bhattacharya A; Furey ML
    Adv Pharmacol; 2020; 89():357-386. PubMed ID: 32616213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scopolamine and depression: a role for muscarinic antagonism?
    Hasselmann H
    CNS Neurol Disord Drug Targets; 2014; 13(4):673-83. PubMed ID: 24938776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of muscarinic receptor mechanisms in antidepressant drug action.
    Witkin JM; Smith JL; Golani LK; Brooks EA; Martin AE
    Adv Pharmacol; 2020; 89():311-356. PubMed ID: 32616212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.
    van Enkhuizen J; Janowsky DS; Olivier B; Minassian A; Perry W; Young JW; Geyer MA
    Eur J Pharmacol; 2015 Apr; 753():114-26. PubMed ID: 25107282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamatergic modulators: the future of treating mood disorders?
    Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
    Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins: Neurobiological underpinnings and mechanisms in mood disorders.
    Walker AJ; Kim Y; Borissiouk I; Rehder R; Dodd S; Morris G; Nierenberg AA; Maes M; Fernandes BS; Dean OM; Williams LJ; Eyre HA; Kim SW; Zoungas S; Carvalho AF; Berk M
    Neurosci Biobehav Rev; 2021 Sep; 128():693-708. PubMed ID: 34265321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic induction of cholinergic system up-regulation and supersensitivity in affective disorders research.
    Dilsaver SC
    J Clin Psychopharmacol; 1986 Apr; 6(2):65-74. PubMed ID: 3517080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment-resistant mood disorders].
    Machado-Vieira R; Soares JC
    Braz J Psychiatry; 2007 Oct; 29 Suppl 2():S48-54. PubMed ID: 17713691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of brain-derived neurotrophic factor in mood disorders.
    Hashimoto K; Shimizu E; Iyo M
    Brain Res Brain Res Rev; 2004 May; 45(2):104-14. PubMed ID: 15145621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical models: status of basic research in depression.
    Nestler EJ; Gould E; Manji H; Buncan M; Duman RS; Greshenfeld HK; Hen R; Koester S; Lederhendler I; Meaney M; Robbins T; Winsky L; Zalcman S
    Biol Psychiatry; 2002 Sep; 52(6):503-28. PubMed ID: 12361666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.